Squarepoint’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-449,796
| Closed | -$18.1M | – | 4368 |
|
|
2026
Q1 | $18.1M | Buy |
449,796
+257,640
| +134% | +$5.55M | 0.02% | 761 |
|
|
2025
Q4 | $4.83M | Buy |
192,156
+139,322
| +264% | +$3.27M | 0.01% | 1483 |
|
|
2025
Q3 | $1.2M | Sell |
52,834
-276,558
| -84% | -$6.45M | ﹤0.01% | 2535 |
|
|
2025
Q2 | $5.7M | Sell |
329,392
-113,401
| -26% | -$2.1M | 0.01% | 1371 |
|
|
2025
Q1 | $9.68M | Buy |
442,793
+275,831
| +165% | +$7.62M | 0.01% | 1045 |
|
|
2024
Q4 | $5.33M | Buy |
166,962
+76,621
| +85% | +$2.3M | 0.01% | 1578 |
|
|
2024
Q3 | $2.61M | Buy |
90,341
+29,083
| +47% | +$1.08M | ﹤0.01% | 1890 |
|
|
2024
Q2 | $2.35M | Buy |
+61,258
| New | +$2.77M | ﹤0.01% | 1932 |
|
|
2022
Q4 | – | Sell |
-101,085
| Closed | -$6.9M | – | 3156 |
|
|
2022
Q3 | $6.9M | Buy |
101,085
+50,705
| +101% | +$3M | 0.03% | 591 |
|
|
2022
Q2 | $2.28M | Buy |
50,380
+31,082
| +161% | +$1.42M | 0.01% | 1107 |
|
|
2022
Q1 | $981K | Buy |
+19,298
| New | +$852K | ﹤0.01% | 1599 |
|
|
2021
Q3 | – | Sell |
-5,344
| Closed | -$338K | – | 2876 |
|
|
2021
Q2 | $338K | Buy |
+5,344
| New | +$276K | ﹤0.01% | 2436 |
|
|
2020
Q4 | – | Sell |
-26,422
| Closed | -$797K | – | 2887 |
|
|
2020
Q3 | $797K | Buy |
26,422
+3,632
| +16% | +$109K | 0.01% | 1116 |
|
|
2020
Q2 | $744K | Buy |
22,790
+12,799
| +128% | +$411K | 0.01% | 1098 |
|
|
2020
Q1 | $268K | Sell |
9,991
-10,368
| -51% | -$368K | 0.01% | 1345 |
|
|
2019
Q4 | $623K | Sell |
20,359
-23,538
| -54% | -$651K | ﹤0.01% | 1635 |
|
|
2019
Q3 | $1.06M | Sell |
43,897
-20,103
| -31% | -$553K | 0.01% | 1198 |
|
|
2019
Q2 | $1.62M | Buy |
64,000
+17,889
| +39% | +$364K | 0.02% | 965 |
|
|
2019
Q1 | $899K | Buy |
46,111
+3,207
| +7% | +$50.4K | 0.01% | 1160 |
|
|
2018
Q4 | $566K | Buy |
42,904
+21,804
| +103% | +$335K | 0.01% | 1183 |
|
|
2018
Q3 | $375K | Buy |
+21,100
| New | +$390K | ﹤0.01% | 1441 |
|
Other funds holding APLS
Squarepoint's APLS Position: Q2 2026 in Review
Squarepoint sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 449,796 shares — an estimated $18.1M sold.
Squarepoint first reported a position in APLS in Q3 2018 and held it in 21 quarters. The position peaked at $18.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Squarepoint reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Squarepoint sold 449,796 Apellis Pharmaceuticals shares in Q2 2026, an estimated $18.1M.
- Squarepoint first reported a position in Apellis Pharmaceuticals in Q3 2018 and held it in 21 quarters.
- Squarepoint's Apellis Pharmaceuticals position peaked at $18.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.